TG Therapeutics Inc. (NASDAQ: TGTX) announced the completion of enrollment in a Phase 3 trial evaluating subcutaneous BRIUMVI for relapsing ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE